Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 2/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.44 |
| ▸ | HTR3B | O95264 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LCAT | P04180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275290 | 0.85 | HTR3A (0.62) | OGAHRH3ALOX5HTR1AHTR2A | |
| SCHEMBL22547430 | 0.84 | ALOX5 (0.51) | PHGDHOGAHRH3ALOX5HTR1A | |
| SCHEMBL6529664 | 0.84 | ALOX5 (0.51) | PHGDHOGAHRH3ALOX5HTR1A | |
| SCHEMBL3934891 | 0.83 | HRH3 (0.55) | PHGDHOGAHRH3ALOX5HTR1A | |
| SCHEMBL30770805 | 0.83 | ALOX5 (0.50) | PHGDHOGAHRH3ALOX5HTR1A | |
| SCHEMBL3916764 | 0.81 | ALOX5 (0.52) | PHGDHOGAHRH3ALOX5HTR1A | |
| SCHEMBL15725480 | 0.81 | HRH3 (0.65) | PHGDHOGAHRH3ALOX5HTR1A | |
| SCHEMBL14083328 | 0.81 | OGA (0.47) | PHGDHOGAHRH3ALOX5HTR1A | |
| SCHEMBL13706046 | 0.80 | CYP2C19 (0.58) | OGAHRH3ALOX5HTR1AHTR2A | |
| SCHEMBL2412819 | 0.80 | HTR3E (0.58) | OGAHRH3ALOX5HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | claimed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | PHGDH 3389/4885OGA 1301/4885HRH3 412/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | PHGDH 3389/4885OGA 1301/4885HRH3 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.